replic
oncolyt
virus
repres
new
agent
potenti
util
cancer
therapi
aim
effect
erad
tumor
cell
without
affect
normal
tissu
sever
differ
dna
rna
virus
current
evalu
efficaci
select
toward
cancer
far
report
describ
potenti
use
coronavirusbas
oncolyt
agent
cancer
virotherapi
despit
number
featur
make
coronavirus
potenti
attract
purpos
coronavirus
positivestrand
rna
virus
consist
nucleocapsid
contain
approxim
kb
genom
nucleocapsid
n
protein
surround
envelop
carri
three
membran
protein
spike
envelop
e
matrix
spike
glycoprotein
respons
viru
entri
syncytia
format
bind
cellular
receptor
induc
membran
specif
interact
aminotermin
spike
protein
domain
cognat
induc
conform
chang
spike
protein
domain
trigger
membran
fusion
process
conform
chang
requir
physic
interact
two
heptad
repeat
hr
region
occur
domain
prevent
interact
use
peptid
correspond
region
block
membran
fusion
bind
peptid
respect
coronavirus
exhibit
strict
speci
specif
determin
coronaviru
felin
infecti
periton
viru
fipv
instanc
select
infect
induc
syncytium
format
felin
cell
via
receptor
felin
aminopeptidas
n
fapn
likewis
recombin
felin
mous
hepat
viru
fmhv
deriv
mous
hepat
viru
mhv
carri
chimer
spike
ectodomain
fipv
spike
protein
also
infect
fuse
felin
cell
fapn
molecul
consequ
speci
restrict
tropism
fipv
mhv
nonpathogen
human
cell
howev
tropism
barrier
allevi
coronavirus
replic
cell
differ
thu
fipv
mhv
may
potenti
convert
specif
oncolyt
agent
treatment
human
cancer
spike
protein
would
recogn
receptor
human
tumor
cell
toward
develop
recombin
coronavirus
select
human
tumor
tropism
first
set
investig
effect
fipv
mhv
erad
vitro
human
cancer
cell
express
viru
receptor
allow
comparison
two
virus
cell
assess
fipv
instead
mhv
chimer
coronaviru
fmhv
abil
kill
human
cancer
cell
artifici
express
fapn
subsequ
investig
whether
fipv
fmhv
could
target
human
cancer
cell
express
epiderm
growth
factor
receptor
egfr
molecul
commonli
overexpress
mani
type
cancer
associ
poor
prognosi
respons
cancer
purpos
prepar
bispecif
singlechain
variabl
fragment
scfv
antibodi
bind
one
side
fipv
fmhv
spike
protein
side
human
egfr
antibodi
inde
function
specif
target
devic
find
justifi
develop
coronavirus
oncolyt
agent
determin
whether
nonhuman
coronavirus
infect
kill
human
cancer
cell
host
speci
barrier
determin
specif
receptor
recognit
allevi
fipv
fmhv
redirect
human
cancer
cell
via
viru
receptor
fapn
first
suscept
tumor
cell
line
hela
widr
fipv
fmhv
success
demonstr
transient
transfect
cell
fapn
express
plasmid
follow
viru
inocul
data
shown
control
inocul
cell
transfect
fapn
express
construct
show
detect
fipv
fmhv
infect
confirm
infect
requir
appropri
receptor
express
studi
fipv
fmhv
propag
cytotox
syncytia
format
requir
host
cell
stabl
receptor
express
therefor
hela
cell
line
stabli
express
fapn
produc
fipv
fmhv
test
growth
characterist
helafapn
ovcarfapn
cell
figur
evid
infect
fapnexpress
human
cancer
cell
virus
fipv
fmhv
result
typic
rapid
product
progeni
viru
determin
potenc
fipv
fmhv
kill
human
cancer
cell
helafapn
ovcarfapn
cell
inocul
variou
multipl
fipv
fmhv
cell
viabil
measur
sever
time
point
infect
fipv
fmhv
effici
kill
type
cell
dosedepend
manner
onset
cell
death
found
occur
earli
h
inocul
follow
infect
multipl
infect
moi
virus
complet
elimin
ovcarfapn
helafapn
monolay
within
h
respect
infect
lower
moi
appar
requir
multipl
round
infect
result
death
nearli
cell
within
h
figur
furthermor
infect
cell
clearli
show
membran
fusion
typic
coronaviru
replic
figur
also
determin
whether
nonhuman
coronavirus
abl
erad
human
cancer
cell
vitro
solid
tumor
model
multilay
tumor
spheroid
offer
use
model
assess
virusmedi
erad
tumor
tissu
model
alreadi
employ
studi
potenc
oncolyt
adenovirus
adenoassoci
ovcarfapn
spheroid
establish
inocul
fmhv
plaqu
form
unit
pfu
spheroid
comparison
oncolyt
effect
adenoviru
type
pfuspheroid
also
measur
sever
day
postinocul
pi
cell
viabil
determin
figur
day
pi
clear
decreas
viabil
observ
spheroid
inocul
either
viru
day
ovcarfapn
spheroid
infect
pfu
fmhv
essenti
destroy
wherea
spheroid
infect
pfu
partial
erad
howev
note
cytolyt
entri
mechan
coronavirus
adenovirus
differ
distinctli
make
direct
comparison
entir
valid
result
confirm
light
microscop
analysi
figur
establish
fipv
fmhv
infect
destroy
cancer
cell
entri
barrier
overcom
want
develop
gener
method
target
virus
suitabl
antigen
express
cell
end
construct
bispecif
scfv
combin
antigen
bind
domain
antibodi
recogn
fipv
protein
egfr
respect
protein
produc
express
eucaryot
cell
synthesi
secret
verifi
radiolabel
follow
immunoprecipit
cell
lysat
cultur
medium
use
antimyc
antibodi
figur
result
clearli
show
synthesi
secret
approxim
kda
bispecif
singlechain
molecul
investig
whether
scfv
could
serv
adapt
molecul
fipv
fmhv
infect
via
human
egfr
cultur
human
cancer
cell
line
differ
tissu
origin
confirm
express
egfr
figur
inocul
similar
amount
fipv
fmhv
presenc
absenc
bispecif
antibodi
h
inoculum
replac
regular
cultur
medium
incub
cell
continu
h
cell
immunostain
coronaviru
protein
express
seen
figur
cell
line
test
becom
infect
fipv
fmhv
presenc
scfv
contrast
none
cell
stain
posit
inocul
fipv
fmhv
preincub
mock
control
supernat
data
shown
similarli
posit
stain
observ
human
cancer
cell
inocul
control
viru
mhv
presenc
scfv
data
shown
differ
infect
effici
observ
differ
cell
line
egfrhigh
cell
show
highest
suscept
egfrtarget
coronaviru
infect
egfrlow
cell
poorli
infect
cell
line
hela
cell
except
egfrtarget
fipv
exhibit
similar
infect
effici
egfrtarget
fmhv
interestingli
infect
cell
form
syncytia
typic
product
coronaviru
infect
format
infecti
progeni
viru
confirm
monitor
titrat
cell
increas
viral
titer
medium
cell
inocul
fipv
fmhv
typic
growth
curv
obtain
cell
inocul
presenc
bispecif
scfv
figur
confirm
infect
fipv
fmhv
establish
scfv
inde
mediat
human
egfr
protein
test
mous
fibroblast
cell
line
nih
human
egfrexpress
deriv
nih
suscept
fipv
fmhv
presenc
absenc
scfv
illustr
figur
posit
immunostain
coronaviru
protein
obtain
nih
cell
inocul
presenc
scfv
result
demonstr
fipv
fmhv
infect
otherwis
refractori
nih
cell
requir
adapt
molecul
express
human
egfr
evid
specif
interact
bispecif
scfv
human
egfr
obtain
studi
effect
egfr
antibodi
scfv
coronaviru
infect
hela
cell
incub
monoclon
antibodi
prior
inocul
fmhv
presenc
scfv
figur
show
infect
block
almost
complet
confirm
direct
interact
egfr
requir
similarli
necess
interact
fipv
spike
protein
scfv
confirm
incub
fmhv
without
antifipv
spike
monoclon
antibodi
ad
scfv
inocul
hela
cell
anti
antibodi
inhibit
infect
demonstr
scfv
bind
viru
spike
protein
order
function
target
adaptor
figur
sever
human
cancer
cell
line
infect
egfrtarget
fipv
fmhv
show
fusion
typic
coronavirus
see
figur
syncytium
format
import
determin
cytotox
spread
coronavirus
therefor
import
investig
syncytium
format
infect
neighbor
cell
result
undefin
interact
specif
bridg
scfv
end
cell
inocul
fmhv
scfv
medium
h
subsequ
cultur
anoth
h
presenc
absenc
scfv
thu
scfv
either
present
continu
support
infect
syncytium
format
briefli
mediat
target
infect
remov
scfv
h
significantli
reduc
syncytium
format
approxim
fourfold
nuclei
per
syncytium
data
repres
averag
amount
nuclei
per
syncytium
measur
three
independ
experi
indic
standard
deviat
henc
scfv
promot
fusion
fmhv
envelop
target
cell
also
fusion
fmhvinfect
neighbor
cell
coronavirus
use
class
membran
fusion
common
number
envelop
viru
hr
region
occur
spike
protein
play
instrument
role
mechan
involv
conform
chang
spike
protein
subsequ
receptor
bind
result
interact
domain
necessari
drive
membran
fusion
process
process
inhibit
specif
use
peptid
correspond
hr
domain
show
recent
order
investig
bispecif
antibodytarget
fipv
fmhv
infect
induct
syncytia
also
depend
conform
rearrang
viral
spike
protein
test
sensit
process
hrderiv
peptid
end
prepar
peptid
correspond
region
fipv
protein
initi
studi
peptid
abil
block
fipv
fmhv
infect
felin
cell
illustr
fmhv
figur
b
addit
inocul
felin
cell
abrog
infect
syncytium
format
respect
next
determin
whether
scfv
infect
syncytium
format
also
sensit
peptid
end
fmhv
target
toward
egfr
cell
presenc
absenc
seen
figur
addit
peptid
reduc
scfv
infect
syncytium
format
thu
process
seem
util
membran
fusion
process
similar
nativ
coronaviru
despit
tremend
research
effort
last
decad
natur
diseas
caus
despit
signific
new
insight
acquir
cancer
remain
one
common
caus
death
actual
treatment
still
reli
major
part
classic
approach
surgeri
radiotherapi
chemotherapi
clearli
novel
creativ
method
need
complement
convent
treatment
option
recent
use
virus
potenti
tool
anticanc
therapi
gain
consider
first
exploratori
studi
demonstr
two
import
featur
make
coronavirus
attract
purpos
abil
target
virus
human
tumor
cell
subsequ
infect
erad
cell
nonhuman
coronavirus
fipv
fmhv
appear
possess
strong
capac
kill
human
cancer
cell
abl
enter
cell
artifici
express
receptor
consist
earlier
observ
mhv
gallagh
observ
rapid
effici
erad
cancer
cell
probabl
attribut
two
coronavir
featur
first
coronavirus
positivestrand
rna
virus
exhibit
fast
cytoplasm
transcript
process
lead
rapid
viru
protein
synthesi
progeni
viru
product
second
abil
coronavirus
induc
syncytia
infect
noninfect
neighbor
cell
amplifi
cytotox
found
fipv
fmhv
retain
properti
human
cancer
cell
express
viru
receptor
thu
enabl
rapid
cytotox
spread
viru
surround
noninfect
cancer
cell
coronavirus
share
attract
characterist
envelop
virus
fusogen
mutant
herp
simplex
live
attenu
edmonston
b
vaccin
strain
measl
howev
contrast
virus
coronavirus
fipv
fmhv
normal
incap
infect
human
cell
due
restrict
tropism
thu
nativ
tropism
need
abolish
order
specif
limit
access
henc
cytotox
human
cancer
cell
abil
deliber
target
virus
preselect
cell
tremend
challeng
farreach
implic
kind
therapeut
applic
although
abl
demonstr
principl
retarget
coronavirus
exchang
spike
neither
detail
structur
inform
knowledg
technolog
requir
purpos
redesign
spike
bind
given
antigen
present
avail
therefor
altern
also
potenti
versatil
tool
embark
develop
bispecif
adapt
thu
redirect
nonhuman
coronavirus
fipv
fmhv
egfrexpress
cell
construct
bispecif
antibodi
molecul
scfv
bind
felin
spike
egfr
latter
chosen
frequent
overexpress
human
cancer
cell
inocul
fipv
fmhv
onto
number
differ
egfrexpress
human
cancer
cell
line
variou
tissu
origin
presenc
scfv
result
infect
replic
subsequ
format
syncytia
target
infect
complet
depend
presenc
antibodi
effici
gener
correl
level
egfr
express
cancer
cell
observ
similar
nativ
coronaviru
infect
fusion
effici
also
correl
host
cell
receptor
result
impli
bispecif
antibodymedi
target
approach
principl
appli
direct
coronavirus
cell
surfac
antigen
appropri
antibodi
ie
hybridoma
cell
line
avail
success
applic
bispecif
adapt
viral
tumor
therapi
depend
among
other
cell
surfac
antigen
prefer
uniqu
tumor
use
tumorspecif
marker
yet
identifi
futur
work
reveal
whether
occur
specif
induc
tumor
cell
interestingli
attenu
measl
viru
recent
describ
receptor
densiti
could
also
determin
preferenti
tumor
indic
even
overexpress
certain
receptor
tumor
cell
may
result
tumor
select
infect
subsequ
cell
kill
may
also
import
target
coronavirus
sinc
similar
receptor
densiti
depend
describ
import
coronaviru
infect
syncytia
applic
also
depend
suffici
local
presenc
adapt
might
achiev
incorpor
adapt
gene
sequenc
viral
genom
viru
produc
target
devic
demonstr
principl
recent
target
condit
replic
adenovirus
thu
adenovirus
express
bispecif
scfv
target
egfr
show
enhanc
oncolyt
replic
egfrposit
adenoviru
receptorneg
cancer
foreign
gene
express
also
achiev
coronavirus
show
recent
insert
differ
report
gene
variou
posit
mhv
coronavirus
exhibit
high
mutat
rate
prone
recombin
applic
adaptermedi
target
tumor
thu
rais
seriou
safeti
question
particularli
regard
possibl
gener
virus
acquir
capac
infect
human
cell
independ
target
devic
question
address
sever
option
reduc
risk
alreadi
exist
one
use
coronavirus
lack
specif
virul
gene
show
recent
virus
strongli
attenu
natur
host
anoth
option
combin
delet
nonessenti
virul
gene
genom
rearrang
reorgan
order
structur
protein
gene
found
mhv
toler
without
loss
reduc
risk
gener
viabl
virus
recombin
circul
field
virus
entri
coronavirus
cell
normal
requir
bind
spike
receptor
follow
seri
structur
rearrang
protein
eventu
lead
merg
viral
cellular
membran
appear
bispecif
antibodymedi
entri
well
antibodymedi
induct
syncytia
use
fusion
mechan
illustr
clearli
inhibitori
effect
peptid
interest
find
fusion
process
actual
take
place
whether
instanc
necessari
conform
chang
protein
induc
interact
antibodi
trigger
bind
egfr
altern
fusion
may
mediat
spike
effect
bind
rather
conform
chang
induc
free
spike
upon
interact
undefin
molecul
target
cell
particular
condit
experienc
viru
taken
endosom
evid
latter
mechan
might
obtain
studi
whether
infect
also
achiev
use
bispecif
antibodi
bind
viru
protein
one
envelop
protein
e
involv
fusion
process
eleg
applic
target
principl
recent
describ
anoth
envelop
viru
measl
viru
receptor
bind
membran
fusion
function
divid
two
differ
envelop
protein
hemagglutinin
h
fusion
f
protein
respect
scfv
carboxytermin
append
type
ii
membran
glycoprotein
h
viru
success
target
cell
express
distinguish
obvious
append
egfr
bind
moieti
scfv
amino
terminu
coronaviru
protein
might
also
expand
target
possibl
virus
recombin
fipv
strain
stock
produc
titrat
parallel
felin
cell
yield
titer
tissu
cultur
infecti
dose
respect
wildtyp
produc
titrat
human
embryon
kidney
cell
recombin
vaccinia
viru
contain
bacteriophag
rna
polymeras
gene
use
rna
polymeras
sourc
promoterdriven
product
bispecif
scfv
obtain
b
moss
nih
hela
widr
american
type
cultur
collect
cell
obtain
nc
pedersen
grown
dulbecco
modifi
eagl
medium
dmem
cambrex
bio
scienc
vervier
belgium
contain
fetal
bovin
serum
fb
iu
penicillinml
streptomycinml
life
technolog
ltd
paisley
uk
nihhegfr
cell
nih
obtain
pmp
van
bergen
en
henegouwen
maintain
dmem
contain
fb
iu
penicillinml
streptomycinml
mgml
life
technolog
ltd
paisley
uk
helafapn
ovcarfapn
maintain
medium
supplement
mgml
respect
hybridoma
cell
line
produc
monoclon
antibodi
mab
fipv
spike
cultur
cd
hybridoma
medium
supplement
mm
glutamax
life
technolog
ltd
paisley
uk
ascit
fluid
fipvinfect
cat
kindli
provid
bj
haijema
use
sourc
polyclon
antibodi
fipv
rabbit
antiserum
rais
purifi
mab
direct
fapn
receptor
describ
cultur
supernat
hybridoma
cell
line
use
sourc
mab
direct
fipv
fmhv
spike
egfr
detect
mab
use
cultur
supernat
hybridoma
cell
line
atcc
detect
myctag
scfv
antimyc
antibodi
myc
use
cultur
supernat
hybridoma
cell
line
myc
atcc
express
plasmid
contain
fapn
cdna
control
cytomegaloviru
use
transient
express
fapn
differ
cancer
cell
line
follow
transfect
lipofectamin
plu
reagent
life
technolog
ltd
paisley
uk
transfect
hela
cell
also
cultur
cell
cultur
medium
select
stabl
transfect
hela
cell
clone
two
four
round
limit
dilut
respect
test
suscept
fipv
infect
fapn
express
fluoresc
activ
cell
sorter
fac
analysi
furthermor
fipv
infect
block
antifapn
antibodi
confirm
infect
occur
via
fapn
amount
well
seed
inocul
next
day
viru
moi
pfucel
h
serumfre
cultur
medium
cell
wash
three
time
pb
cultur
h
sever
time
point
pi
medium
harvest
centrifug
min
rpm
store
analysi
amount
viru
produc
time
point
pi
determin
end
point
titrat
felin
cell
amount
helafapn
ovcarfapn
cell
seed
per
well
infect
triplic
variou
amount
fipv
fmhv
sever
time
point
inocul
cell
cultur
h
roch
diagnost
gmbh
mannheim
germani
measur
viabil
express
rel
uninfect
control
cell
subtract
background
valu
incub
absenc
cell
threedimension
multilay
spheroid
produc
incub
ovcarfapn
cell
well
coat
multi
purpos
agaros
roch
diagnost
gmbh
mannheim
germani
pb
h
spinnerplatform
set
rpm
subsequ
spheroid
cultur
day
reach
diamet
approxim
use
infect
experi
spheroid
infect
total
volum
cultur
day
incub
h
measur
directli
spheroidcontain
well
viabil
express
rel
uninfect
control
spheroid
subtract
background
valu
incub
absenc
spheroid
statist
signific
differ
group
determin
ttest
hybridoma
cell
line
use
isol
mrna
use
quickprep
micro
mrna
purif
kit
amersham
pharmacia
biotech
europ
gmbh
freiburg
germani
mous
scfv
modulerecombin
phage
antibodi
system
amersham
use
gener
scfv
mrna
isol
hybridoma
cell
cdna
produc
rtpcr
accord
mous
scfv
modul
protocol
variabl
domain
heavi
chain
vh
light
chain
vl
antibodi
cdna
isol
pcr
use
vh
vl
primer
scfv
isol
system
fragment
clone
separ
pgemteasi
clone
vector
promega
madison
usa
sequenc
introduc
residu
middl
linker
fusion
pcr
perform
join
fragment
configur
via
linker
dna
linker
dna
consist
two
primer
compris
part
linker
sequenc
scfv
underlin
flank
sequenc
overlap
result
ser
linker
subsequ
pcr
assembl
scfv
dna
amplifi
restrict
site
ad
use
rs
primer
scfv
isol
system
result
dna
fragment
contain
sfii
site
noti
site
subsequ
clone
pgemteasi
sequenc
sequenc
compar
sequenc
independ
fragment
result
correct
clone
name
plasmid
digest
sfii
noti
isol
bp
scfv
ligat
pcantab
deriv
digest
sfii
noti
result
scfv
direct
egfr
isol
noti
digest
ligat
configur
noti
site
downstream
scfv
creat
three
ala
linker
two
scfv
fragment
result
express
vector
contain
bp
bispecif
cdna
construct
encod
antispik
scfv
link
antiegfr
scfv
fusion
aminotermin
signal
sequenc
carboxytermin
myc
tag
control
cmv
promot
determin
whether
scfv
produc
secret
cultur
medium
subconflu
monolay
cell
tissu
cultur
dish
inocul
pfucel
h
subsequ
transfect
h
without
dna
plasmid
dna
use
lipofectin
life
technolog
ltd
paisley
uk
h
cell
starv
min
cystein
methioninefre
modifi
eagl
medium
contain
mm
hepe
ph
fb
medium
replac
similar
medium
contain
vitro
celllabel
mixtur
amersham
pharmacia
biotech
europ
gmbh
germani
h
cell
either
lyse
label
medium
cell
replac
normal
cultur
medium
incub
continu
h
cell
lyse
tesv
lysi
buffer
mm
trishcl
ph
mm
edta
mm
nacl
mm
pmsf
triton
clear
medium
tesv
lysi
buffer
ad
protein
immunoprecipit
medium
lyse
cell
use
antimyc
antibodi
dilut
immun
complex
adsorb
pansorbin
cell
calbiochem
la
jolla
usa
describ
equal
volum
immunoprecipit
analyz
contain
polyacrylamid
product
scfv
subconflu
monolay
cell
inocul
moi
h
transfect
h
mock
transfect
plasmid
dna
use
lipofectin
life
technolog
ltd
paisley
uk
medium
refresh
h
harvest
h
centrifug
min
rpm
clear
cell
debri
mock
supernat
supernat
contain
bispecif
scfv
load
onto
sucros
cushion
centrifug
min
rpm
clear
supernat
viru
store
aliquot
use
supernat
cell
infect
transfect
plasmid
dna
use
control
supernat
singl
batch
scfv
control
supernat
use
experi
describ
determin
optim
amount
scfv
use
target
infect
fipv
moi
preincub
h
variou
amount
scfv
inocul
total
volum
cell
well
h
inoculum
replac
regular
cultur
medium
incub
cell
continu
h
immunostain
serum
direct
fipv
protein
perform
stain
cell
count
number
plot
amount
scfv
use
titrat
result
reveal
optim
amount
bispecif
antibodi
need
maxim
target
effici
standard
condit
scfv
antibodi
increas
rather
decreas
level
infect
presum
excess
antibodi
inoculum
may
bind
egfr
cell
therebi
block
use
viru
cell
inocul
fipv
preincub
mock
control
supernat
remain
neg
data
shown
cell
incub
antifipv
ascit
fluid
dilut
antimhv
serum
dilut
follow
goat
anticat
peroxidas
dako
glostrup
denmark
dilut
swine
antirabbit
peroxidas
dako
glostrup
denmark
dilut
respect
cell
stain
aec
brunschwig
amsterdam
netherland
accord
manufactur
protocol
analyz
light
microscopi
determin
whether
scfv
interact
egfr
hela
cell
per
well
incub
without
hybridoma
supernat
contain
mab
min
order
block
interact
egfr
scfv
next
cell
inocul
h
pfu
fmhv
preincub
scfv
h
total
volum
thereaft
cell
fix
permeabil
immunostain
presenc
fmhv
number
infect
cell
count
use
light
microscopi
interact
scfv
spike
protein
analyz
incub
pfu
fmhv
without
hybridoma
supernat
contain
antifmhv
antibodi
h
incub
scfv
ad
h
incub
total
volum
next
infect
mix
inocul
hela
cell
per
well
h
cell
fix
permeabil
immunostain
presenc
fmhv
number
infect
cell
determin
use
light
microscopi
amount
cell
per
well
inocul
moi
h
fmhv
preincub
scfv
h
cell
wash
three
time
pb
incub
presenc
absenc
scfv
immunostain
perform
h
infect
number
nuclei
per
syncytium
determin
light
microscopi
product
peptid
correspond
amino
acid
fipv
spike
protein
acc
pcr
fragment
prepar
use
templat
sequenc
cdna
clone
contain
fipv
spike
peptid
express
escherichia
coli
purifi
quantifi
describ
sensit
normal
fusion
process
studi
inocul
felin
fmhv
moi
presenc
absenc
peptid
h
effect
target
fusion
process
analyz
prepar
parallel
two
inocul
mixtur
preincub
fmhv
scfv
h
peptid
ad
one
mixtur
two
cultur
human
cell
wash
pb
inocul
moi
h
infect
mix
cell
fix
permeabil
stain
presenc
fmhv
use
antimhv
rabbit
antiserum
number
infect
cell
count
use
light
microscopi
sensit
fusion
process
normal
infect
felin
cell
analyz
inocul
cell
fmhv
moi
h
wash
three
time
pb
incub
h
cultur
medium
without
peptid
similar
analysi
fusion
target
infect
cultur
cell
inocul
moi
fmhv
preincub
scfv
h
next
cell
wash
three
time
pb
incub
h
cultur
medium
without
peptid
cell
fix
permeabil
immunostain
presenc
fmhv
protein
number
nuclei
per
syncytium
count
light
microscop
